undamentalytics Newsletter
Sign in

Akebia Therapeutics, Inc. revenue

Akebia Therapeutics, Inc.'s revenue was $236m in fiscal 2025, up 47.5% on the year before. Since fiscal 2016 ($1.5m) it has grown at a compound 75.0% a year. Over the last twelve months it was $219m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue002181208335295212292195160236219
Growth on the year before———+>999%+14.6%+61.3%−12.0%−28.2%+38.2%−33.5%−17.7%+47.5%—
Gross profit————200190−26120712097197174

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $227M 96.2% ▲ 49.4%
Auryxia $182M 79.9% ▲ 19.3%
Vafseo $45.8M 20.1% —
License Collaboration and Other Revenue $8.9M 3.8% ▲ 10.8%

From Akebia Therapeutics, Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Akebia Therapeutics, Inc. $219m 7.5% 2.9%
Puma Biotechnology, Inc. $231m -2.9% 0.2%
Ideaya Biosciences, Inc. $234m -70.1% 94.0%
Anaptysbio, Inc $238m 92.9% 163.9%
Rhythm Pharmaceuticals, Inc. $240m 53.5% 76.3%
Valneva SE $197m 7.6% —

Compare with peers

Head to head: AKBA vs PBYIAKBA vs IDYAAKBA vs ANABAKBA vs VALN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Akebia Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Akebia Therapeutics, Inc.